Free Trial
NASDAQ:RNXT

RenovoRx Q4 2023 Earnings Report

RenovoRx logo
$1.03 +0.03 (+3.00%)
Closing price 03:59 PM Eastern
Extended Trading
$1.04 +0.01 (+0.97%)
As of 04:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

RenovoRx EPS Results

Actual EPS
-$0.17
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

RenovoRx Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

RenovoRx Announcement Details

Quarter
Q4 2023
Time
N/A
Conference Call Date
Monday, April 1, 2024
Conference Call Time
7:00AM ET

Upcoming Earnings

RenovoRx's Q1 2025 earnings is scheduled for Thursday, May 15, 2025, with a conference call scheduled at 4:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Earnings Documents

RenovoRx Earnings Headlines

RenovoRx (RNXT) Projected to Post Earnings on Friday
URGENT: Someone's Moving Gold Out of London...
People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “gold analysts” have it all wrong… They tell you to invest in gold ETFs - because the popular mining ETFs will someday catch fire and close the price gap with spot gold.
See More RenovoRx Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like RenovoRx? Sign up for Earnings360's daily newsletter to receive timely earnings updates on RenovoRx and other key companies, straight to your email.

About RenovoRx

RenovoRx (NASDAQ:RNXT), a clinical-stage biopharmaceutical company, focuses on developing proprietary targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is RenovoGem, an oncology drug-device combination product, consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. The company has a research collaboration with Imugene Limited to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.

View RenovoRx Profile

More Earnings Resources from MarketBeat